Brian Murphy


Brian Murphy


Mr. Murphy is a AAA Commercial Arbitrator and served as a Lead Administrative Patent Judge at the PTAB, where he presided over nearly 200 America Invents Act post grant trial proceedings.
Mr. Murphy is a AAA Commercial Arbitrator and served as a Lead Administrative Patent Judge at the PTAB, where he presided over nearly 200 America Invents Act post grant trial proceedings.


Brian Murphy is a partner at Haug Partners in New York City.

Mr. Murphy provides strategic advice and representation to clients and their counsel involved in PTAB post grant trial proceedings, district court litigation, and Federal Circuit appeals.  Mr. Murphy also conducts mock PTAB and Federal Circuit oral arguments and acts as an expert witness.  He has represented clients in the pharmaceutical, biotechnology, medical device, consumer products, telecommunications, semiconductor, electronics, and automotive industries.

Mr. Murphy serves as an AAA Commercial Arbitrator (Life Sciences and IP). Mr. Murphy served as co-lead trial counsel for claimant in a seven-month arbitration and evidentiary hearing in 2021.  The claim arose from a pharmaceutical asset purchase and commercialization agreement, and the arbitration resulted in a $45 million Final Award for claimant.

From 2013 through 2017, Mr. Murphy served as an Administrative Patent Judge at the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent & Trademark Office in Alexandria, Virginia.  Mr. Murphy presided over nearly 200 post grant review trial proceedings (Inter Partes Review; Post Grant Review; Covered Business Method Review), including interlocutory discovery, motion proceedings and oral argument. He drafted numerous substantive decisions.  For three years he served as a Lead Judge on the PTAB leadership team, training and mentoring Administrative Patent Judges.

Mr. Murphy has more than 35 years of experience advising and representing clients in patent litigation and intellectual property licensing and related agreement negotiations.  Mr. Murphy has been lead trial counsel in patent, unfair competition, and Section 337 litigations in federal district court, the PTAB, the International Trade Commission, and private arbitration.  He has represented patent owners and accused patent infringers in hundreds of patent infringement cases.  His experience includes Hatch-Waxman ANDA patent litigation regarding chemical compounds (APIs), compositions, formulations, excipients, medicinal and organic chemistry, treatment methods, and polymorphs.  His biotechnology patent experience includes therapeutic antibodies, PEGylated proteins, protein chemistry, immunoassay diagnostics, and cell media.


  • IPR2013-00582 Baxter Int’l v. Millenium Biologix, FWD Paper 48 (PTAB March 18, 2015).
  • IPR2015-01187 and IPR2015-01227 Cox Commc’ns. v. AT&T Intell. Prop. II, FWD Paper 59 (-1187) and Paper 70 (-1227).
  • CBM2014-00149 (-150, -151, -153) Par Pharm., Inc. v. Jazz Pharms., Inc., DI Paper 12 (PTAB January 13, 2015).
  • IPR2014-00510 STATS LLC v. Hockeyline, Inc., FWD Paper 33 (PTAB September 15, 2015).
  • IPR2014-00235 Apple, Inc. v. THX, Ltd., FWD Paper 39 (PTAB June 9, 2015).
  • IPR2015-00085 Daifuku Co., Ltd. v. Murata Machinery, Ltd., FWD Paper 66 (PTAB May 3, 2016).
  • IPR2015-00545 and IPR2015-00551 Amneal Pharms., Inc. v. Jazz Pharms., Inc., FWD Paper 69 (-545) and Paper 70 (-551) (PTAB July 27, 2016).
  • IPR2015-01723 Coalition for Affordable Drugs IX LLC v. Bristol Myers Squibb Co., DI Paper 10 (PTAB February 22, 2016).
  • PGR2016-00018 B.R.A.HMS. GmbH v. Becton, Dickinson and Co., DI Paper 8 (PTAB November 2, 2016).
  • PGR2017-00008 Grunenthal GmbH v. Antecip Bioventures II LLC, DI Paper 7 (PTAB July 7, 2017).


  • Med-El v. Advanced Bionics AG, IPR2020-01016 Paper 42 (PTAB March 21, 2022)
  • Hatchtech Pty v. Dr. Reddy’s Labs., ICDR Case Number: 01-20-0015-1940 (June 2021)
  • NOF Corp. v. Nektar Therapeutics, IPR2019-01395 Paper 21 (PTAB Feb. 4, 2020)
  • CSL Behring v. Shire Viropharma, IPR2019-00459 Paper 8 (PTAB July 2, 2019)
  • Roquette Freres v. SPI Pharma, Inc., CA No. 06-540 (GMS)(D. Del.)
  • DuPont Air Products Nanomaterials v. Cabot Microelecs., CV 06-2952-PHX (D. Ariz.)
  • Glaxo Group Ltd. v. Amneal Pharm., CA 2:08-CV-493-WJM-MF (D.N.J.)
  • Glaxo Group Ltd. v. Teva Pharms. USA, Inc., Civil Action No. 04-cv-171 (KAJ) (D. Del.)
  • Daiichi Pharm. Co. v. Apotex, Inc., 441 F. Supp. 2d 672 (D.N.J. 2006), rev ‘d, 501 F.3d 1254 (Fed. Cir. 2007)
  • Daiichi Pharm. Co. v. Apotex, Inc., 380 F. Supp. 2d 478 (D.N.J. 2005)
  • Daiichi Pharm. Co. v. Bausch & Lomb Inc., Civil Action No. 02-6112 (SDW) (D.N.J.)
  • SmithKline Beecham Corp. v. Excel Pharms., Inc., 356 F.3d 1357 (Fed. Cir. 2004)
  • TAP Pharm. v. Atrix Labs, Inc. and Sanofi-Synthelabo, 2004 U.S. Dist. LEXIS 17118 (N.D. Ill. 2004)
  • Glaxo Wellcome Inc. v. Genentech, Inc., 136 F. Supp. 2d 316 (D. Del. 2001)
  • Glaxo Wellcome Inc. v. Genentech, Inc., 107 F. Supp. 2d 477 (D. Del. 2000)
  • IDEC Pharms., Inc. v. SmithKline Beecham Corp., Civil Action No. 01 CV 1638 JM (JAH) (S.D. Cal.)
  • Glaxo Wellcome Inc. v. Pharmadyne Corp., 32 F. Supp. 2d 265 (D. Md. 1998)
  • Glaxo Wellcome Inc. v. Ben Venue Laboratories, Inc., 1998 U.S. Dist. LEXIS 19774 (N.D. Ohio 1998)
  • Glaxo Inc. v. Geneva Pharms. Inc., 1995 U.S. Dist. LEXIS 21897 (D.N.J. 1995)
  • Hy-Ko Products Co. v. The Hillman Group, Inc., Case No. 5:08cv1961 (N.D. Ohio)
  • In the Matter of Certain Semiconductor Memory Devices and Products Containing Same, Investigation No. 337-TA-470 (ITC) (2002-2003)
  • In the Matter of Certain Erasable Programmable Read Only Memories, Inv. No. 337-TA- 276, USITC Pub. No. 2196 (March 16, 1989), affd in part, reversed in part and vacated in part, Intel Corp. v. U.S. ITC, 946 F.2d 821 (1991)
  • General Instrument Corp. v. Scientific-Atlanta, Inc., Civil Action No. 89-4624 (HAA) (D.N.J.)
  • General Instrument Corp. v. Intel Corp., Civil Action No. 87-1635 PHX-RGS (D. Az.)
  • General Instrument Corp. v. Intel Corp., Civil Action No. 88-0323 PHX RCB (D. Az.)
  • Novamedix Ltd. v. Kinetic Concepts Inc., Civil Action No. SA-92-CA-0177 (FB) (W.D. Tex.)
  • N.A.D., Inc. v. Johnson & Johnson, Civil Action No. 91-2241 (NLS) (E.D. Pa.)
  • Conopco, Inc. [Unilever] v. Princeton Biomeditech, Inc., Civil Action No. 97-6254 (KAH) (D.N.J.) (reported as Inverness Medical Switz. v. Princeton Biomeditech Corp., 309 F.3d 1365 (Fed. Cir. 2002))
  • Conopco, Inc. [Unilever] v. Warner-Lambert Co., Civil Action No. 97-CV-101 (KSH) (D.N.J.) (reported as Inverness Medical Switz. v. Warner Lambert, 309 F.3d 1373 (Fed. Cir. 2002))
  • Procter & Gamble Co. v. Lever Brothers Co., Civil Action No. C-1-98-390 (HJW)(W.D. Ohio)[MBP1]


  • AIPLA 2022 Annual Meeting, “In the Interests of Justice: Metes and Bounds of Additional Discovery at the PTAB,” Oct. 28, 2022
  • NYIPLA PTAB Committee, PTAB Judge for “Mock PTAB Hearing: How To Handle Difficult Issues During A PTAB Trial,” Nov. 10, 2020
  • PTAB Bar Association Annual Meeting, “Amending Patent Claims During PTAB Proceedings: Strategy Considerations,” Sept. 24, 2020
  • “PTAB Proceedings in a Post-Aqua Landscape: What Patent Owners Need to Know”, Speaker, The Knowledge Group, Webinar, July 26, 2018
  • “The PTAB Live: Thoughts on Practice, Procedure, IPRs and More in the World of Pharmaceutical Patent Validity Challenges”, ACI Paragraph IV Disputes Conference, NYC, April 25, 2018
  • “Advanced Topics in PTAB Practice”, NYIPLA Patent Litigation Committee, NYC, February, 28, 2018
  • “PTAB Patent Proceedings: Best Practices and Strategies You Must Know For 2018”, The Knowledge Group, Webinar, February 20, 2018
  • “Hot Topics and Issues in the Biosimilars Space: Part Two”, NYIPLA Patent Litigation and Women in IP Law committees, NYC, February 1, 2018
  • “The Interplay Between Litigation and Post Grant Trials at the PTO and Update on PTAB Practice”, New York State Bar Association, NYC, January 23, 2018
  • ACI Paragraph IV Disputes PTAB panelist, 2015-2017
  • PLI PTAB Panelist, Spring 2017
  • AIPLA Bench and Bar PTAB panelist, 2015


  • Named Top IPR Attorney 2022 (Patexia)
  • New York Super Lawyer: Intellectual Property Litigation (2006-2008, 2013)


  • Fordham University School of Law, (J.D.)
  • University of Virginia (B.A. – Chemistry)


  • State Bar of New York
  • United States Patent and Trademark Office
  • United States Court of Appeals for the Federal Circuit
  • United States District Courts for the Southern and Eastern Districts of New York


  • NYIPLA PTAB Committee (2018-Present)
  • PTAB Bar Association (2018-Present)
  • Intellectual Property Owners Association, U.S. Post-Grant Patent Office Practice Committee (2018-2019)
  • Co-Chair: ACI Paragraph IV Disputes – American Conference Institute (2007-2011)
  • Vice-Chair: Hatch-Waxman Committee, Intellectual Property Owners Ass’n (2004-2007)
  • Past Member: American Intellectual Property Law Ass’n – Patent Litigation Comm.
  • Past Member: Fordham Univ. School of Law – Alumni Advisory Committee (1998-2003)
  • Member; Chair: Hastings-on-Hudson, N.Y. Zoning Board of Appeals (2003-2013)



New York City
745 Fifth Avenue, 10th Floor,
New York, NY 10151
745 Fifth Avenue, 10th Floor, New York, NY 10151